Robert W. Mutter, MD, Mayo Clinic, discusses research involving partial breast irradiation and multi-modality therapy in early-stage breast cancer. #bcsm #ACRO24 onclive.com/view/data-cont…

As the field of orthopedic oncology continues to evolve and orthopedic oncologists assume primary stewardship of patients with metastatic bone disease, healing and practicing self-care techniques is key for clinicians. R. Lor Randall UC Davis Comprehensive Cancer Cent #oncology onclive.com/view/as-orthop…

HER2 gene expression demonstrated value as a prognostic and predictive factor for treatment outcomes in patients with KRAS wild-type mCRC enrolled in the phase 3 CALGB/SWOG-80405 trial. @USCNorris #oncology #crcsm onclive.com/view/her2-expr…

In a previous episode of #OncLiveOnAir , Drs D. Ross Camidge and Su discuss the aspects of medicine that strengthened Dr Su’s interest in oncology and the details of delivering lung cancer care in China. #oncology #lcsm onclive.com/view/camidge-a…

Ruben Olivares, MD, of @ClevelandClin discusses focal therapy in the management of #ProstateCancer with #OncLive HERE: onclive.com/view/dr-olivar…

Oliver Dorigo, MD, PhD, discusses the investigation of CRX100 in patients with recurrent, platinum-resistant ovarian cancer. Stanford Medicine #ovca #oncology onclive.com/view/early-dat…

The European Commission has approved cilta-cel for the treatment of patients with relapsed/refractory multiple myeloma who have received 1 or more prior lines of therapy. Universidad de Navarra #mmsm onclive.com/view/european-…

The database of the phase 1/2 EOGBM1-18/ROSALIE trial evaluating EO2401 in combination with nivolumab with or without bevacizumab in patients with recurrent glioblastoma has been locked. #btsm #oncology onclive.com/view/rosalie-t…

The FDA has granted breakthrough therapy designation to ziftomenib for the treatment of NPM1-mutant acute myeloid leukemia. U.S. FDA #leusm onclive.com/view/fda-grant…

The FDA’s approval of cilta-cel represents a key advancement in relapsed/refractory multiple myeloma, potentially allowing patients to experience a treatment-free period following administration. Saad Z. Usmani MD MBA FACP 🇺🇸🇵🇰 Memorial Sloan Kettering Cancer Center #oncology #MedTwitter #mmsm . onclive.com/view/cilta-cel…

Although FAK inhibition alone has displayed modest activity to date, there is interest in developing FAK-targeted therapies for combination regimens. FCS Foundation The James Memorial Sloan Kettering Cancer Center #oncology #medtwitter onclive.com/view/fak-inhib…

The combination of avutometinib and defactinib elicited preliminary efficacy signals in the phase 2 RAMP 201 trial, leading to the further evaluation of the combination in low-grade serous ovarian cancer. @sitemancenter #ovca #gyncsm onclive.com/view/avutometi…

In case you missed any, below is a recap of every episode of OncLive On Air that aired in March 2024. #OncLiveOnAir #MedTwitter #Oncology onclive.com/view/revisit-e…

Hear Kara N. Maxwell, MD, PhD, as she discusses strategies to optimize the utility of genetic testing to better inform decision-making in prostate cancer treatment. #pcsm #oncology onclive.com/view/dr-maxwel…

Pembrolizumab plus chemotherapy has been approved by Health Canada for the first-line treatment of adult patients with locally advanced, unresectable, or metastatic, HER2-negative gastric or GEJ adenocarcinoma. #oncology onclive.com/view/first-lin…

The FDA has mandated that the boxed warning for all approved CAR T-cell therapies be updated to include the serious risk of T-cell malignancies. #mmsm #lymsm #leusm #oncology onclive.com/view/fda-requi…

MRI-Guided Neoadjuvant Chemotherapy Could be Used in HR-/HER2+ Breast Cancer
#bcsm #oncology #MedTwitter
onclive.com/view/mri-guide…

A unique approach combining genomic and sensitivity testing with machine learning was feasible for guiding treatment selection in pediatric cancers. Nature Medicine #oncology #pediatriccancer onclive.com/view/functiona…

Alectinib has been approved by the FDA for use as adjuvant treatment following tumor resection in patients with ALK-positive NSCLC whose tumors are at least 4 cm or node positive. U.S. FDA #lcsm #oncology onclive.com/view/fda-appro…

Matthew S. Johnson, MD, discusses a pilot study of Y-90 radioembolization plus pembrolizumab in patients with poor-prognosis hepatocellular carcinoma. IU School of Medicine #hcc #oncology onclive.com/view/y-90-radi…